Informações:
Falhas:
ID
11981
Descrição
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control; ODM derived from: https://clinicaltrials.gov/show/NCT02483936
Link
https://clinicaltrials.gov/show/NCT02483936
Palavras-chave
Versões (1)
- 30/08/2015 30/08/2015 -
Titular dos direitos
ODM derived from: https://clinicaltrials.gov/show/NCT02483936
Transferido a
30 de agosto de 2015
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Arterial Hypertension NCT02483936
Eligibility Arterial Hypertension NCT02483936
- StudyEvent: Eligibility
Similar models
Eligibility Arterial Hypertension NCT02483936
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
consent
Item
signed consent of the patient;
boolean
C0514044 (UMLS CUI [1])
cardiovascular; participants; hypertension; stage; high; very
Item
participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the brazilian society of cardiology (2010), who are being treated with monotherapy.
boolean
C0085580 (UMLS CUI [1])
clinically significant; investigator; disease; study
Item
patients with any clinically significant disease that in the investigator opinion can not participate in the study;
boolean
C0973444 (UMLS CUI [1])
blood pressure; randomization; hypertension; diagnosis; screening; visit
Item
secondary hypertension diagnosis or blood pressure above 190x100 mmhg in the screening/randomization visit;
boolean
C0155616 (UMLS CUI [1])
immunocompromised; obesity
Item
morbid obesity or immunocompromised patients;
boolean
C0085393 (UMLS CUI [1])
C0028756 (UMLS CUI [2])
C0028756 (UMLS CUI [2])
diastolic blood pressure; participants; systolic; arms
Item
participants with greater than 10 mmhg difference in the measurements of systolic or diastolic blood pressure between the two arms;
boolean
C0151244 (UMLS CUI [1])
participants; upper
Item
participants who do not have the two upper limbs;
boolean
C1140618 (UMLS CUI [1])
participants
Item
participants with important electrocardiographic changes;
boolean
C0855329 (UMLS CUI [1])
creatinine clearance
Item
creatinine clearance - less than 60 ml / min;
boolean
C0373595 (UMLS CUI [1])
cardiovascular; moderate; severe; events
Item
history of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months;
boolean
C0745136 (UMLS CUI [1])
C1561291 (UMLS CUI [2])
C1561291 (UMLS CUI [2])
microalbuminuria; urine
Item
microalbuminuria urine sample greater than 30 mg/g;
boolean
C0730345 (UMLS CUI [1])
history of hypersensitivity to mistletoe
Item
patients with history of hypersensitivity to any of the formula compounds;
boolean
CL421546 (UMLS CUI [1,1])
C0042785 (UMLS CUI [1,2])
C0020517 (UMLS CUI [1,3])
C0042785 (UMLS CUI [1,2])
C0020517 (UMLS CUI [1,3])
pregnancy and lactation
Item
pregnancy or risk of pregnancy and lactation patients;
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0006147 (UMLS CUI [1,2])
clinical trial; study; year
Item
participation in clinical trial in the year prior to this study;
boolean
C0008976 (UMLS CUI [1])